Simone Chevalier
- Full Professor;Ìý
- McGill Urology Director of Research
B.Sc., M.Sc. Ph.D.
- Studentships, Medical research Council of Canada
- FRQS Scholarships (all levels, Junior and Senior)
- Recipient of Kathryn Rolph Award, Department of Surgery, Ï㽶ÊÓƵ
- Commemorative Plaque for Pioneers/Investigators of the Research Centre, Maisonneuve-Rosemont Hospital
- Certificate of Excellence awarded by PROCURE Alliance and a Plaque in Recognition of Exceptional Scientific Direction and Tireless Dedication to the Prostate Cancer Biobank
Urologic Oncology Research Facilities, Research Institute, Ï㽶ÊÓƵ Health Centre, Glen Campus, Room E02-4374
Ìý
OncologyÌý
I joined the McGill Dept of Surgery as an Associate Professor in 1994 to become the director of new research facilities being built at the RI-MUHC of the Montreal General Hospital for the Urologic Oncology Research Team. We integrated the Cancer Research Program of the RI-MUHC at the Glen site in 2015. Being a prostate cancer scientist since the very beginning of my career, I became deeply involved in the creation of the pan-provincial PROCURE Prostate Cancer Biobank in 2007 and directed its operations for 10 years. I remain a consultant for matters related to the Biobank. We recently undertook a project aiming to prospectively interrogate tumours of specific subsets of patients in this cohort of 2,000 patients to identify molecular drivers of prostate cancer lethality and to trace best markers back in liquid biopsies throughout the disease trajectory of the same patients. This type of translational research has become of paramount importance to impact on outcome and death from prostate cancer. I am now a Senior Scientist and as such, I always gladly take time for patients who contact me to know more on ongoing research and novelties in the field of cancer, and particularly prostate cancer.
Chevalier S, Moffett S, Turcotte E, Luz M, Chauvette L, Derbekyan V, Scarlata E, Zouanat F, Aprikian AG, Anidjar M.
The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumours and metastases.
EJNMMI Res. 2015 Dec;5(1):77. PMID: 26714499 PMCID: DOI:
Pellerin Charles, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S.
A simple variable number of tandem repeat-based genotyping strategy for the detection of handling errors and validation of sample identity in biobanks.
Biopreserv Biobank. 2016 Oct;14(5)383-390. PMID: 27327090; DOI:
Michel, Brimo F, Chevalier S, Scarlata E, McKercher G, O’Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A.
Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
BJU Int, 2019 Apr;123(4):624-631; PMID: 30113732; DOI: ; Epub 2018 Sep 11.
Aprikian Saro, Luz M, Brimo F, Scarlata E, Hamel L, Cury F L, Tanguay S, Aprikian A, Kassouf W, Chevalier S. Improving Ultrasound-Based Prostate Volume Estimation.
BMC Urology 2019 Jul 24;19(1):68. doi: 10.1186/s12894-019-0492-2
Vesval Quentin, Wissing MD, Derderian S, Hamel L, Côté N, Vanhuysse M, Ferrario C, Aprikian AG, Bladou F, Chevalier S. Liquid biopsy-based targeted gene screening highlights tumour cell subtypes in patients with advanced prostate cancer Molecular Oncology, Under revision 2021